GEN-725

Dose escalation phase - primary purpose: to evaluate the safety and tolerability of GEN-725 tablets in patients with advanced solid tumors, explore dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and determine the recommended dose expansion (RDE); secondary purpose: to evaluate the pharmacokinetic (PK) characteristics of GEN-725 tablets in patients with advanced solid tumors; to preliminarily evaluate the anti-tumor efficacy of GEN-725 tablets in patients with advanced solid tumors; to evaluate the effect of GEN-725 tablets on the quality of life of patients with advanced solid tumors; exploratory purpose: to explore the expression level of programmed cell death ligand-1 (PD-L1) in tumor tissues and its correlation with efficacy; to explore changes in the tumor microenvironment: to evaluate the changes in bone marrow-derived suppressor cells (MDSCs), lymphocyte typing (CD4+T, CD8+T, regulatory T cells [Treg], etc.) and cytokines (interferon [IFN], interleukin [IL], etc.) in whole blood before and after administration, and their correlation with efficacy. Dose expansion phase - Primary objective: to evaluate the anti-tumor efficacy of GEN-725 tablets in patients with advanced solid tumors; Secondary objectives: to evaluate the safety of GEN-725 tablets in patients with advanced solid tumors; to evaluate the PK characteristics of GEN-725 tablets in patients with advanced solid tumors; to evaluate the effect of GEN-725 tablets on the quality of life of patients with advanced solid tumors. Exploratory objectives: Same as the dose escalation phase.